SULFACHLORPYRAZIN - natrium - 30% pulvis solubilis 30 g/100 g Bulharsko - bulharčina - БАБХ (Българска агенция по безопасност на храните)

sulfachlorpyrazin - natrium - 30% pulvis solubilis 30 g/100 g

ФАРМА ВЕТ ООД - sulfachlorpyrazin-натрий монохидрат - перорален прах - 30 g/100 g - агнета, зайци, кокошки, пилета, пуйки, телета, ярета

SULFACHLORPYRAZIN NATRIUM Bulharsko - bulharčina - БАБХ (Българска агенция по безопасност на храните)

sulfachlorpyrazin natrium

СУДАХИМ ЕООД - sulfachlorpyrazin натрий - прах за прилагане във вода за пиене - мин. 99.0 g/100 g - агнета, зайци, птици, пуйки, ярета

Enerzair Breezhaler Európska únia - bulharčina - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - астма - Лекарства за обструктивна заболявания на дихателните пътища, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Regkirona Európska únia - bulharčina - EMA (European Medicines Agency)

regkirona

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - Имунни серуми и имуноглобулини - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Riltrava Aerosphere Európska únia - bulharčina - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - Белодробна болест, хронична обструктивна болест - Лекарства за обструктивна заболявания на дихателните пътища, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.